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Abstract	  
Individuals	  with	  Alpha-­‐1	  antitrypsin	  deficiency	  (AATD)	  have	  mutations	   in	  the	  SERPINA1	  
gene	  causing	  genetic	  susceptibility	  to	  early	  onset	  lung	  and	  liver	  disease	  that	  may	  result	  
in	  premature	  death.	  Environmental	  interactions	  have	  a	  significant	  impact	  in	  determining	  
the	  disease	  phenotype	  and	  outcome	   in	  AATD.	  The	  aim	  of	   this	  study	  was	  to	  assess	   the	  
impact	  of	  smoke	  exposure	  on	  the	  clinical	  phenotype	  of	  AATD	  in	  Ireland.	  
Clinical	   demographics	   and	   available	   thoracic	   computerised	   tomography	   (CT)	   imaging	  
were	   evaluated	   from	   139	   PiZZ	   individuals	   identified	   from	   the	   Irish	   National	   AATD	  
Registry.	   Clinical	   information	   was	   collected	   by	   questionnaire.	   Data	   was	   analysed	   to	  
assess	  AATD	  disease	  severity	  and	  evaluate	  predictors	  of	  clinical	  phenotype.	  
Questionnaires	   were	   collected	   from	   107/139	   (77%)	   and	   thoracic	   CT	   evaluation	   was	  
available	   in	   72/107	   (67.2%).	   74%	   of	   respondents	   had	   severe	   Chronic	   Obstructive	  
Pulmonary	   Disease	   (COPD)	   (GOLD	   stage	   C	   or	   D).	   Cigarette	   smoking	   was	   the	   greatest	  
predictor	  of	  impairment	  in	  FEV1	  and	  DLCO	  (%predicted)	  and	  the	  extent	  of	  emphysema	  
correlated	   most	   significantly	   with	   DLCO.	   Interestingly	   the	   rate	   of	   FEV1	   decline	   was	  
similar	   in	   ex-­‐smokers	   when	   compared	   to	   never	   smokers.	   Passive	   smoke	   exposure	   in	  
childhood	  resulted	  in	  a	  greater	  total	  pack	  year	  smoking	  history.	  Radiological	  evidence	  of	  
bronchiectasis	  was	  a	  common	  finding	  and	  associated	  with	  increasing	  age.	  
The	   Irish	   National	   AATD	   Registry	   facilitates	   clinical	   and	   basic	   science	   research	   of	   this	  
condition	  in	  Ireland.	  This	  study	  illustrates	  the	  detrimental	  effect	  of	  smoke	  exposure	  on	  
the	   clinical	   phenotype	   of	   AATD	   in	   Ireland	   and	   the	   benefit	   of	   immediate	   smoking	  
cessation	  at	  any	  stage	  of	  lung	  disease.	  
	   	  
Introduction	  
Alpha-­‐1	  antitrypsin	  deficiency	  (AATD)	   is	  an	  autosomal	  co-­‐dominant	   inherited	  condition	  
that	   results	   in	   reduced	   circulating	   levels	   of	   AAT	   protein	   and	   predisposes	   affected	  
individuals	   to	   early	   onset	   lung	   and	   liver	   disease.	   It	   was	   first	   described	   by	   Laurell	   and	  
Eriksson	  in	  1963(1)	  and	  has	  since	  been	  recognised	  as	  one	  of	  the	  most	  common	  genetic	  
conditions	  affecting	  people	  of	  Western	  European	  descent.	  
Despite	   its	  prevalence	  AATD	   is	  a	   condition	   that	   is	   rarely	  diagnosed.	  Detection	   rates	   in	  
some	  countries	  are	  as	  less	  than	  10%	  of	  the	  at	  risk	  population(2),	  this	  may	  relate	  to	  low	  
awareness	  of	  AATD	  among	  physicians	  which	  can	  often	  lead	  to	  significant	  delays	  before	  
the	  diagnosis	  is	  reached(3).	  The	  WHO,	  ATS	  and	  ERS	  advocate	  targeted	  testing	  for	  AATD	  
in	  all	   individuals	  with	  COPD,	  non-­‐responsive	  asthma,	  cryptogenic	   liver	  disease	  and	  first	  
degree	   relatives	   of	   individuals	  with	  AATD(4).	   This	   approach	  has	   led	   to	   higher	   rates	   of	  
detection	   in	   the	   populations	   most	   at	   risk	   of	   lung	   disease,	   though	   widespread	   under	  
recognition	  of	  the	  condition	  remains	  (5,6).	  
The	  development	  of	  national	   registries	   for	   individuals	  with	  AATD	  can	  address	  many	  of	  
the	   shortcomings	   in	   our	   knowledge	   of	   the	   disorder;	   facilitate	   understanding	   of	   the	  
natural	  history	  of	  AATD;	  promote	  patient	  education	  and	  dissemination	  of	   information;	  
aid	  recruitment	  for	  clinical	  research	  studies;	  and	  assist	   international	  collaboration	  with	  
colleagues	   through	   research	   initiatives	   (7,8).	   In	   cystic	   fibrosis,	   a	   disease	  with	   a	   similar	  
prevalence,	   the	   establishment	   of	   registries	   has	   led	   to	   significant	   improvements	   in	  
patient	  related	  outcomes	  (9).	  
Irish	  registry	  experience	  
The	  establishment	  of	   the	   Irish	  National	  AATD	  Targeted	  Detection	  Programme	   in	   2004	  
facilitated	  an	   increased	  detection	  rate	  of	  AATD,	  and	  in	  2007	  the	  National	  AAT	  Registry	  
was	  created.	  The	  registry	  is	  maintained	  by	  the	  Irish	  Alpha	  One	  Foundation.	  The	  national	  
referral	  centre	  for	  AATD	  in	  Ireland	  is	  based	  in	  Beaumont	  Hospital,	  Dublin.	  Referrals	  are	  
received	  from	  across	  the	  island	  of	  Ireland	  covering	  a	  population	  of	  6.38	  million	  people.	  
Given	  the	  relatively	  small	  geographic	  size	  of	  the	  country,	  all	   individuals	  with	  AATD	  can	  
potentially	  be	  assessed	  in	  a	  single	  centre.	  
Our	  programme	  has	  detected	  over	  12,000	   individuals,	   leading	   to	   the	  diagnosis	  of	  250	  
PiZZ	   and	   185	   PiSZ	   individuals.	   In	   addition	   to	   the	   common	   AATD	   alleles,	   we	   have	  
identified	  a	  number	  of	  rare	  mutations	   including	  two	  newly	  described	  null	  mutations,	  a	  
Null/Null	  homozygote	  and	  MMalton/MMalton	  homozygote	  (10).	  In	  the	  past	  year	  our	  registry	  
information	   technology	   systems	   have	   been	   upgraded	   to	   enable	   more	   efficient	   data	  
entry	  and	  extraction.	  In	  addition	  our	  website	  has	  been	  updated	  to	  be	  more	  user	  friendly	  
and	  expand	  the	  resources	  and	  information	  available	  for	  individuals	  and	  family	  members	  
of	  those	  affected	  by	  AATD	  (www.alpha1.ie).	  
AATD	  epidemiology	  in	  Ireland	  
The	   gene	   frequency	   for	   the	   Z	   protein	   is	   most	   prevalent	   in	   northern	   and	   western	  
European	  countries	  with	  severe	  deficiency	  (PiZZ)	  affecting	  up	  to	  1:1500	  (2),	  though	  it	  is	  
less	  common	  in	  countries	  of	  predominantly	  Western	  European	  descent	  such	  as	  regions	  
of	   North	   America	   and	   the	   Antipodes	   (11,12).	   In	   Ireland	   1:2104	   individuals	   are	   PiZZ	  
homozygotes,	   though	   in	   our	   targeted	   detection	   program	   1:71	   tested	   were	   PiZZ	  
homozygotes	  highlighting	  the	  effectiveness	  of	  the	  targeted	  detection	  approach	  (5).	  	  
The	  detection	  of	  asymptomatic	   individuals	  (non-­‐index)	  through	  the	  family	  screening	  of	  
probands	   is	   an	   opportunity	   to	   better	   understand	   the	  natural	   history	   of	  AATD	   (13,14).	  
Targeted	  detection	  will	  invariably	  detect	  many	  MZ	  heterozygotes	  and	  clarification	  of	  the	  
true	  risk	  of	  lung	  disease	  in	  this	  population	  is	  important,	  particularly	  in	  smokers.	  Utilising	  
index	  cases	  identified	  from	  the	  Irish	  Registry,	  it	  has	  been	  established	  that	  ever-­‐smoking	  
PiMZ	   individuals	  have	  an	   increased	   risk	   for	  COPD	  and	   this	   risk	   is	   attenuated	   in	  never-­‐
smokers	  (15).	  
Clinical	  trial	  research	  
Augmentation	   therapy	   for	   AATD	   was	   approved	   for	   clinical	   use	   in	   Ireland	   in	   2007,	  
however	  it	  remains	  inaccessible	  for	  patient	  use	  due	  to	  concerns	  about	  the	  significance	  
of	   its	   clinical	   efficacy,	   the	   high	   cost	   of	   treatment,	   and	   lack	   of	   reimbursement	   for	  
treatment	  by	  the	  Health	  Service	  in	  Ireland.	  The	  Irish	  National	  AATD	  Registry	  has	  proven	  
to	  be	  an	  excellent	  resource	  for	  the	  recruitment	  of	  Irish	  patients	  with	  severe	  AATD	  into	  
clinical	   trials.	   Our	   centre	   continues	   to	   participate	   in	   a	   number	   of	   international	  
randomised	   controlled	   clinical	   trials,	   including	   intravenous	  AAT	   augmentation	   therapy	  
(NCT00261833,	   NCT00670007)	   and	   nebulised	   AAT	   therapy	   (NCT01217671).	   The	  
facilitation	   of	   clinical	   trial	   research	   into	   AATD	   in	   Ireland	   raises	   awareness	   of	   AATD,	  
advances	   scientific	   knowledge,	   and	   importantly	   facilitates	   earlier	   access	   to	  
augmentation	  therapy	  for	  patients	  affected	  by	  the	  condition.	  
	   	  
Original	  Research:	  
Aim	  
To	  assess	  the	  impact	  of	  smoke	  exposure	  on	  the	  clinical	  phenotype	  of	  AATD	  in	  Ireland.	  
Methods	  
Study	  population	  
The	  National	   AATD	   registry	  was	   used	   to	   identify	   all	   individuals	  with	   a	   confirmed	   PiZZ	  
phenotype	   currently	   living	   in	   Ireland	   in	   January	   2014.	   Registry	   participants	   who	   had	  
undergone	   full	   clinical	   evaluation	   within	   the	   past	   five	   years	   at	   the	   national	   referral	  
centre	   in	   Beaumont	   Hospital	   were	   selected	   for	   this	   study	   and	   clinical	   demographics	  
were	  recorded.	  All	  participants	  provided	  written	  informed	  consent,	  which	  was	  approved	  
by	  the	  Beaumont	  Hospital	  Research	  Ethics	  Committee.	  
Pulmonary	   function	   testing	   was	   performed	   in	   all	   participants	   according	   to	   American	  
Thoracic	  Society	  standards	   (16);	  post	  bronchodilator	  FEV1,	  FVC	  percent	  predicted,	  and	  
gas	   transfer	   (DLCO)	   measured	   by	   the	   single	   breath	   carbon	   monoxide	   method	   were	  
recorded.	  Pulmonary	  function	  test	  results	  from	  the	  preceding	  five	  years	  were	  recorded;	  
the	  annualised	  rate	  of	  FEV1	  decline	  was	  determined	  by	  regression	  analysis	  in	  those	  with	  
three	  or	  more	  sequential	  results	  over	  a	  time	  period	  of	  one	  year	  or	  more.	  
Questionnaire	  
Cross-­‐sectional	   data	   was	   collected	   from	   the	   study	   participants	   via	   a	   self-­‐reported	  
questionnaire	  that	  was	  distributed	  by	  post,	  questionnaires	  were	  also	  distributed	  in	  the	  
outpatient	   clinic.	   Each	   returned	   questionnaire	   was	   coded	   to	   enable	   matching	   to	   the	  
relevant	  individual’s	  clinical	  and	  radiological	  information	  and	  subsequently	  anonymised	  
for	  analysis.	  Clinical	  parameters	  were	  recorded;	  age	  of	  diagnosis,	  symptomatic	  detection	  
(index)	   vs.	   family	   screening	   (non-­‐index),	   smoking	   status,	   passive	   smoke	   exposure,	  
occupational	   exposure,	   frequency	   of	   pulmonary	   exacerbations,	   cough,	   sputum	  
production,	  and	  oxygen	  use.	  
Dyspnoea	  scores	  were	  calculated	  using	  the	  five	  point	  modified	  Medical	  Research	  Council	  
score	   (mMRC)	   and	   health	   status	   in	   the	   previous	  week	  was	   determined	   using	   a	   visual	  
analogue	   scale	   (VAS)	   scored	   between	   0	   and	   100.	   Pack-­‐year	   smoking	   history	   was	  
determined	   by	   the	   function	   of	   number	   of	   cigarettes	   smoked	   per	   day	   and	   total	   years	  
smoked	  
Radiology	  
High	   Resolution	   CT	   images	  were	   obtained	   on	   a	   Siemens	   16-­‐slice	   scanner.	   All	   patients	  
were	  imaged	  while	  supine	  and	  inspiratory	  images	  were	  obtained	  from	  the	  lung	  apices	  to	  
the	   costophrenic	   angles.	   Scanning	   parameters	   were	   120	  kV	   and	   90	  mA.	   A	   modified	  
version	  of	  Bhalla's	  scoring	  system	  for	  thin	  section	  CT	  in	  patients	  with	  AATD	  was	  applied	  
to	   each	   scan	   (17,18).	   All	   lobes	   were	   individually	   assessed	   for	   purposes	   of	   evaluating	  
severity	   of	   emphysema,	   bronchiectasis	   and	   peribronchial	   thickening.	   All	   criteria	   were	  
scored	  on	   a	   scale	   of	   0-­‐3.	  Once	   scores	  were	   assigned	   to	   each	  of	   the	  parameters,	   they	  
were	   added	   to	   the	   patient's	   individual	   score	   to	   a	   maximum	   of	   21.	   Higher	   scores	  
therefore	  indicate	  greater	  severity.	  Two	  radiologists	  with	  a	  specialist	  interest	  in	  thoracic	  
radiology	  reviewed	  all	  scans	  independently;	  a	  consensus	  opinion	  was	  then	  determined.	  
Both	  radiologists	  were	  blinded	  to	  the	  clinical	  severity	  of	  AATD	  when	  scoring.	  	  
Statistical	  analysis	  
Data	   was	   analysed	   using	   GraphPad	   Prism	   v7.0	   and	   STATA	   v13.0	   was	   employed	   for	  
stepwise	  multiple	  regression	  modelling.	  Statistical	  significance	  was	  determined	  as	  a	  two-­‐
tailed	  p-­‐value	  <0.05.	  Characteristics	  of	  the	  respondents	  were	  summarised	  using	  number	  
and	  percentage	  of	  participants	  in	  each	  category.	  Pearson’s	  correlation	  coefficients	  were	  
used	   to	   identify	   significant	  bivariate	   relationships.	  To	  determine	   factors	   that	   influence	  
the	   severity	   of	   disease,	   significant	   relationships	   identified	   on	   univariate	   analysis	  were	  
entered	   as	   independent	   variables	   into	   a	   stepwise	   multiple	   regression	   analysis	   with	  
ascertainment	   (index	   vs.	   non-­‐index)	   and	   smoking	   status	   assessed	   separately	   as	   the	  
dependent	  variables.	   	  
Results	  
Response	  
A	  total	  of	  204	  PiZZ	   individuals	  were	   identified	  from	  the	  National	  AATD	  Registry.	  Seven	  
individuals	   (3.4%)	   died	   within	   the	   preceding	   twelve	   months.	   Questionnaires	   were	  
distributed	  to	  139	  individuals	  who	  had	  attended	  Beaumont	  Hospital	  within	  the	  past	  five	  
years.	  The	   response	   rate	  was	  107/139	   (77%)	  and	  clinical	  demographics	  were	  available	  
for	  all	   respondents.	  Thoracic	  CT	   imaging	  was	  available	   in	  72/107	   (67.2%)	  and	   this	  was	  
analysed	   separately.	   21/107	   (19.6%)	   of	   respondents	   were	   currently	   receiving	  
intravenous	  AAT	  augmentation	  therapy.	  	  
GOLD	  classification	  
Respondents	  were	  classified	  according	  to	  the	  updated	  GOLD	  document	  (19).	  17	  (16%)	  of	  
respondents	   had	   no	   spirometric	   evidence	   of	   obstructive	   airway	   disease	   and	   were	  
asymptomatic.	   7(6.5%)	   were	   classified	   as	   GOLD	   group	   A,	   4	   (3.7%)	   group	   B,	   33	   (31%)	  
group	  C	  and	  46	  (43%)	  as	  group	  D.	  83/107	  (77.6%)	  of	  respondents	  reported	  usage	  of	  a	  
combined	   corticosteroid/LABA	   inhaler,	   with	   58/107	   (54.2%)	   reporting	   inhaled	   LAMA	  
usage.	   DLCO	   correlated	   well	   with	   FEV1	   (r=0.73,	   p<0.0001),	   and	   emphysema	   (r=0.83,	  
p<0.001),	  	  (Figures	  1A	  and	  1B).	  31/107	  (29%)	  of	  individuals	  used	  portable	  O2	  and	  17	  of	  
these	  were	   reported	  using	   long	   term	  O2	   therapy	   (LTOT).	  A	  DLCO	  value	  of	  <50%	  had	  a	  
sensitivity	  of	  96.7%	  and	  specificity	  of	  76.3%	  to	  predict	  the	  requirement	  for	  portable	  O2	  
usage	  (Figure	  1A).	  
Exacerbations	  
Respondents	  reported	  a	  mean	  frequency	  of	  pulmonary	  exacerbations	  of	  2.1/annum	  in	  
the	   past	   year	   and	   1.82/annum	   over	   a	   two-­‐year	   period.	   Increased	   frequency	   of	  
pulmonary	   exacerbation	  was	   associated	  with	  more	   severe	   impairment	   in	   FEV1,	   lower	  
DLCO	   values	   and	   higher	   emphysema	   scores.	   Interestingly	   there	   was	   no	   association	  
found	  with	   pulmonary	   exacerbations	   or	   radiologically	   assessed	  bronchiectasis,	   though	  
some	  individuals	  with	  a	  more	  severe	  bronchiectatic	  phenotype	  did	  have	  a	  high	  number	  
of	  exacerbations	  in	  the	  past	  two	  years.	  	  
The	   compliance	   rate	   with	   annual	   influenza	   vaccination	   programmes	   was	   high	   and	  
increased	   on	   an	   annual	   basis	   over	   the	   preceding	   four	   years	   from	   62/107	   (58%)	   to	  
81/107	  (75.7%).	  Uptake	  of	  the	  pneumococcal	  vaccine	  was	  also	  high	  at	  76/107	  (71%).	  
Radiological	  findings	  
A	  subgroup	  analysis	  of	  respondents	  was	  performed	  on	  those	  with	  available	  thoracic	  CT	  
imaging	   in	   72/107	   respondents.	   The	   majority	   of	   respondents,	   52/80	   (65%),	   had	  
radiological	  evidence	  of	  emphysema	  that	  was	  most	  severe	  in	  the	  lower	  lobes;	  smokers	  
had	  more	  severe	  emphysema	  at	  an	  earlier	  age	  compared	  to	  never	  smokers	  (Figure	  1C).	  
Radiological	   evidence	   of	   bronchiectasis	  was	   evident	   in	   58/72	   (80.6%)	   of	   respondents,	  
this	  was	  mild	  in	  the	  majority	  of	  cases	  and	  there	  was	  no	  lobar	  preponderance.	  There	  was	  
no	   correlation	   between	   the	   presence	   of	   emphysema	   and	   bronchiectasis,	   (r=-­‐0.1664,	  
p=0.1625),	   (Figure	  1D).	  Bronchiectasis	   increased	  with	  age	   (r=0.41,	  p=0.004),	  and	  while	  
there	   was	   a	   similar	   age-­‐adjusted	   prevalence	   of	   bronchiectasis	   in	   smokers	   and	   never	  
smokers,	  it	  was	  more	  significant	  in	  never	  smokers	  (5.08	  vs.	  2.98,	  p=0.02),	  (Figure	  1E).	  	  
The	   emergence	   of	   different	   radiological	   phenotypes	  was	   evident;	   the	   individuals	  with	  
the	  most	  severe	  bronchiectasis	  had	  little	  or	  no	  evidence	  of	  emphysema	  and	  those	  with	  
the	  most	   severe	  emphysema	  had	  mild	  bronchiectasis.	  Multivariate	   regression	  analysis	  
identified	   increasing	   age	   as	   the	   most	   significant	   risk	   factor	   for	   the	   development	   of	  
bronchiectasis	   independent	   of	   smoking	   history	   (p<0.001).	   Those	   with	   predominant	  
radiological	   evidence	   of	   bronchiectasis	   reported	   less	   cough,	   sputum	   production	   and	  
pulmonary	  exacerbations	  compared	  to	  those	  with	  evidence	  of	  emphysema	  indicating	  a	  
milder	  clinical	  phenotype	  in	  this	  group.	  
Index	  versus	  non-­‐index	  cases	  
Of	  the	  respondents	  72/107	  (67.3%)	  were	  index	  cases	  and	  the	  remaining	  35	  (32.7%)	  non-­‐
index	   cases	   were	   detected	   by	   family	   screening.	   Both	   groups	   were	   well	   matched	   in	  
relation	   to	   symptoms	   of	   cough,	   sputum	   production,	   pulmonary	   exacerbations	   and	  
health	   status	  measurement	   as	   both	   groups	   had	   a	   similar	   percentage	   of	   smokers	   and	  
equal	   pack	   year	   smoking	   history	   (see	   Supplementary	   Table).	   However	   on	   univariate	  
analysis	   index	   cases	   appeared	   to	   have	   significantly	   lower	   FEV1	   values	   (58%	   vs.	   74%,	  
p=0.0273),	   DLCO	   values	   (51%	   vs.	   64%,	   p=0.0126)	   and	   a	   greater	   degree	   of	   airflow	  
obstruction	  (47%	  vs.	  58%,	  p=0.01)	  despite	  similar	  rates	  of	  FEV1	  decline	  (-­‐36.4mls/annum	  
vs.	  -­‐51.2mls/annum,	  p=0.49)	  (Supplementary	  Table).	  In	  the	  univariate	  subgroup	  analysis	  
of	  the	  thoracic	  CT	  data	  it	  was	  also	  found	  that	  index	  cases	  had	  higher	  mean	  emphysema	  
scores	   (9.574	   vs.	   5.52,	   p=0.011).	   However	   on	   adjustment	   for	   age,	   there	   was	   no	  
significant	  difference	  observed	  in	  FEV1,	  airflow	  obstruction	  or	  emphysema	  between	  the	  
groups	   (P=0.51)	   (Supplementary	   Figure	   A).	   As	   both	   index	   and	   non-­‐index	   cases	   had	  
similar	   lifetime	   smoke	  exposure,	   the	  observed	   reduction	   in	   lung	   function	   in	   the	   index	  
cases	  is	  explained	  by	  an	  older	  age	  in	  this	  group.	  	  
	  
	   	  
The	  effect	  of	  smoking	  
71/107	  (66.3%)	  reported	  a	  history	  of	  smoking	  for	  more	  than	  one	  pack	  year.	  The	  majority	  
of	   ever	   smokers	   had	   quit	   prior	   to	   their	   diagnosis	   of	   AATD	   37/71	   (52%).	   30/34	   (88%)	  
people	  reported	  that	  a	  diagnosis	  of	  AAT	  helped	  them	  quit	  within	  a	  median	  time	  of	  two	  
weeks.	  On	  univariate	  analysis	  ever	  smokers	  had	  a	  marked	  reduction	  in	  FEV1,	  DLCO	  and	  
degree	  of	  airflow	  obstruction,	  increased	  breathlessness,	  poorer	  health	  status,	  increased	  
sputum	   production,	   and	   increased	   frequency	   of	   pulmonary	   exacerbations	   (Table	   1).	  	  
Multivariate	   regression	   analysis	   identified	   the	   following	   independent	   variables	   in	   ever	  
smokers;	   increased	  emphysema,	   lower	  DLCO	  values,	   increased	  airflow	  obstruction	  and	  
increased	  sputum	  production.	  This	  would	  be	  consistent	  with	  the	  classic	  phenotypes	  of	  
emphysema	   and	   chronic	   bronchitis	   seen	   in	   COPD.	   Interestingly	   there	   was	   less	  
bronchiectasis	  observed	  in	  the	  ever	  smokers,	  a	  finding	  that	  persisted	  after	  multivariate	  
analysis	  (-­‐2.5,	  95%	  C.I.	  -­‐0.8	  to	  -­‐4.9,	  p=0.047).	  	  
There	   were	   36/107	   (33.6%)	   never	   smokers	   in	   this	   study	   with	   a	   mean	   FEV1	   value	   of	  
83.8%	  and	  DLCO	  of	  71%.	   	  There	  was	  no	  significant	  difference	  in	  the	  annualised	  rate	  of	  
FEV1	  decline	  between	  ever	  smokers	  and	  never	  smokers	  (Supplementary	  Figure	  B).	  This	  
may	  be	  accounted	  for	  by	  a	  number	  of	  possible	  factors;	  all	  ever	  smokers	  were	  now	  ex-­‐
smokers,	   there	  was	   a	   lower	   initial	   FEV1	   in	   the	   smoker	   group,	   the	  modifying	   effect	   of	  
medication	  use,	  and	  the	  survivor	  effect.	  
Subgroup	  analysis	  of	  never	  smokers	  revealed	  that	  index	  cases	  have	  lower	  age	  adjusted	  
FEV1	   (75	   vs.	   95%,	   p=0.042)	   and	   DLCO	   (63	   vs.	   83%,	   p=0.006)	   values	   compared	   to	  
asymptomatic	  never	  smokers	  (Supplementary	  Figure	  C).	  Multivariate	  regression	  analysis	  
confirmed	   the	   association	   for	   lower	   DLCO	   (-­‐9.96%,	   95%	   C.I	   -­‐4.6	   to	   -­‐19.5%,	   p=0.041),	  
indicative	   of	   a	   more	   severe	   phenotype	   in	   symptomatic	   individuals	   with	   AATD	  
(Supplementary	  Figure	  D).	  
88/107	  (82%)	  of	  respondents	  reported	  passive	  smoke	  exposure	  in	  childhood	  with	  a	  large	  
proportion	  of	  these,	  52/88	  (59%),	  reporting	  parental	  passive	  smoke	  exposure.	  Parental	  
smoke	  exposure	  did	  not	  emerge	  as	  an	  independent	  risk	  factor	  for	  poorer	  lung	  function	  
in	  adulthood.	  This	  may	  be	  due	  to	  the	  high	  prevalence	  of	  parental	  smoking	  overall	  and	  
insufficient	  power	   to	  detect	  a	   statistically	   significant	  difference	   in	   lung	   function	   in	  our	  
study	  population.	  Those	  who	  were	  exposed	  to	  passive	  smoke	   in	  childhood	  were	  more	  
likely	   to	   smoke	   in	   adulthood,	   OR	   2.650	   (95%	   confidence	   interval	   0.9645	   to	   7.279,	   p=	  
0.065),	  and	  had	  a	   significantly	  higher	  mean	  pack	  year	   smoking	  history	   (17.25	  vs.	  9.84,	  
p=0.0025),	   see	   Figure	   1F.	   The	   impact	   on	   the	   workplace-­‐smoking	   ban	   was	   assessed;	  
63/107	  (59%)	  reported	  that	  passive	  smoke	  exposure	  had	  reduced	  as	  a	  result	  of	  the	  ban,	  
44/107	   (41%)	   reported	   no	   change,	   while	   no	   subjects	   reported	   increased	   smoke	  
exposure.	  
This	   data	   indicates	   that	   individuals	   with	   AATD	   who	   smoked	   have	   a	   similar	   clinical	  
phenotype	   of	   COPD	   irrespective	   of	   their	   method	   of	   diagnosis	   (index	   vs.	   non-­‐index).	  
Symptomatic	  never	  smokers	  have	  some	  mild	  impairment	  in	  pulmonary	  function	  that	  has	  
brought	  them	  to	  medical	  attention,	  though	  they	  have	  a	  much	  milder	  clinical	  phenotype	  
compared	  to	  those	  who	  ever	  smoked.	   Importantly,	  our	  data	  shows	  that	  asymptomatic	  
never	   smokers	   have	   effectively	   normal	   lung	   function	   and	   no	   impairment	   in	   health	  
status.	  
Occupational	  exposure	  
55/107	  (51.4%)	  of	  respondents	  were	  currently	  in	  full	  time	  employment.	  28/107	  (26.2%)	  
of	  respondents	  reported	  that	  they	  had	  to	  change	  job	  or	  retire	  as	  a	  result	  of	  AATD,	  this	  
group	  had	  significant	  impairment	  in	  lung	  function	  compared	  to	  those	  who	  continued	  in	  
employment	  (mean	  FEV1	  39%	  vs.	  71%,	  p=0.02).	  47/107	  (43.9%)	  of	  respondents	  reported	  
occupational	   inhalational	   exposure	   during	   the	   course	   of	   their	   working	   life,	   the	  
predominant	  exposure	  was	  to	  dust.	  
	   	  
Discussion	  
Determination	  of	  clinical	  phenotype	  in	  AATD	  is	  essential	  for	  a	  greater	  understanding	  of	  
the	   underlying	   pathophysiology	   of	   the	   disease,	   the	   correct	   stratification	   for	   research	  
studies	  and	  therapy,	  and	  to	  prognosticate	  outcomes.	  The	  majority	  of	  respondents	  in	  this	  
study	  had	  GOLD	  group	  D	  COPD	  reflecting	   the	  prevalence	  of	  a	  more	  severe	  phenotype	  
within	  this	  AATD	  registry	  population.	  Objective	  quantification	  of	  pulmonary	  disease	  by	  
thoracic	   CT	   imaging	   enables	   determination	   of	   the	   relationships	   between	   the	   primary	  
pathophysiological	   process	   in	   AATD	   and	   health	   outcomes.	   In	   our	   study,	   pulmonary	  
emphysema	  was	  the	  predominant	  radiological	  finding	  and	  it	  was	  primarily	  found	  in	  ever	  
smokers.	  Regarding	  pulmonary	  function	  measurement,	  impairments	  in	  DLCO	  correlated	  
most	   significantly	  with	  higher	  emphysema	   scores.	  A	  DLCO	  value	  below	  50%	  predicted	  
was	   found	   to	   be	   highly	   predictive	   of	   portable	   oxygen	   requirement	   and	   lower	   DLCO	  
values	   correlated	   strongly	   with	   worsening	   dyspnoea	   and	   health	   status	   measurement	  
outcomes.	  This	  implies	  that	  patients	  with	  DLCO	  values	  below	  50%	  predicted	  may	  benefit	  
from	   assessment	   regarding	   portable	   oxygen	   requirement.	   Recent	   recommendations	  
regarding	   clinical	   trials	   in	   AATD	   suggest	   that	   serial	   CT	   densitometry	   be	   used	   as	   the	  
primary	   endpoint	   to	   demonstrate	   stabilisation	   and	   prevention	   of	   progression	   (20),	  
however	  in	  clinical	  practice	  this	  is	  rarely	  feasible	  and	  our	  data	  would	  suggest	  that	  DLCO	  
may	  be	  employed	  as	  a	  surrogate	  determinant	  of	  disease	  status.	  
There	   remains	   a	   significant	   proportion	   of	   smokers	   with	   AATD	   that	   have	   yet	   to	   be	  
identified,	  and	   this	  may	   relate	   to	  widespread	  under	   recognition	  of	   the	  disorder	   in	   the	  
medical	   profession	   (3).	   In	   this	   study,	   no	   difference	  was	   observed	   between	   index	   and	  
non-­‐index	   cases	   in	   relation	   to	   pulmonary	   symptoms,	  measurements	   of	   lung	   function,	  
and	  severity	  of	  emphysema.	  This	  is	  likely	  explained	  by	  the	  equivalent	  smoke	  exposure	  in	  
both	   groups.	   Smoke	   exposure	   is	   the	   single	   biggest	   determinant	   for	   progression	   of	  
emphysema	   in	   AATD.	   	   Our	   analysis	   of	   the	   influence	   of	   smoke	   exposure	   in	   AATD	  
demonstrates	   the	   presence	   of	   emphysema,	   chronic	   bronchitis	   and	   resultant	   airflow	  
obstruction	  with	  the	  resultant	  classic	  phenotypes	  of	  COPD	  presenting	  at	  a	  young	  age.	  	  
All	   respondents	  had	  stopped	  smoking	  at	   the	   time	  of	   this	   study.	   Individuals	  with	  AATD	  
who	  quit	  smoking	  had	  similar	  rates	  of	  FEV1	  decline	  compared	  to	  never	  smokers	  despite	  
initial	  lower	  FEV1	  values.	  This	  is	  a	  matter	  of	  great	  encouragement	  to	  people	  with	  AATD	  
who	  wish	  to	  give	  up	  smoking	  and	  reflects	  what	  is	  seen	  in	  non-­‐hereditary	  emphysema.	  	  	  
To	   better	   understand	   the	   natural	   history	   of	   AATD	   in	   never	   smokers,	   analysis	   of	   our	  
registry	   revealed	   that	   lung	   function	   is	   normal	   and	   preserved	   beyond	   middle	   age	   in	  
asymptomatic	  never	  smokers.	  This	  is	  an	  important	  observation	  and	  it	  is	  consistent	  with	  
published	  data	  suggesting	  they	  have	  a	   life	  expectancy	  approaching	  that	  of	  the	  general	  
population	   (13,21).	   Though	   the	   confounding	   effects	   of	   genetic	   modifiers	   and	  
environmental	   factors	   should	   be	   taken	   into	   consideration,	   never	   smokers	   with	  
symptomatic	  lung	  disease	  appear	  to	  have	  lower	  FEV1	  and	  DLCO	  values	  indicating	  a	  more	  
severe	  clinical	  phenotype	  than	  asymptomatic	  never	  smokers.	  Our	  data	  implies	  that	  the	  
natural	   history	   of	   AATD	   in	   never	   smokers	   is	   altered	   at	   some	   point	   in	   symptomatic	  
individuals,	   by	   an	   unknown	   precipitant,	   to	   worsen	   their	   condition	   and	   bring	   them	   to	  
medical	  attention.	  	  
Bronchiectasis	  was	  recognised	  early	  to	  be	  a	  pulmonary	  complication	  of	  AATD,	  however	  
the	   true	   prevalence	   and	   clinical	   significance	   of	   bronchiectasis	   in	   the	  AATD	  population	  
remains	   poorly	   understood.	   Observational	   studies	   in	   populations	   of	   non-­‐CF	  
bronchiectasis	   have	   not	   demonstrated	   an	   increased	   prevalence	   of	   the	   condition	  
implying	   that	  AATD	  as	   a	   cause	  of	  bronchiectasis	   is	   uncommon	  and	   that	   it	   occurs	   as	   a	  
result	   of	   co-­‐existent	   emphysema	   (22).	   Our	   data	   would	   contradict	   these	   findings,	  
demonstrating	  that	  radiologically	  detected	  bronchiectasis	  is	  both	  common	  in	  AATD	  and	  
that	  there	  is	  no	  dependent	  relationship	  to	  emphysema	  or	  indeed	  a	  history	  of	  smoking.	  
This	  is	  supported	  by	  similar	  studies	  on	  bronchiectasis	  and	  emphysema	  in	  AATD	  and	  also	  
by	  registry	  data	  showing	  a	  high	  prevalence	  of	  bronchiectasis	  in	  the	  AATD	  population	  in	  
Spain	   and	   Italy	   (14,23).	   Most	   people	   in	   our	   study	   had	   evidence	   of	   mild	   radiological	  
bronchiectasis	  with	  minimal	  associated	  clinical	   symptoms	  such	  as	   increased	   frequency	  
of	   cough	   or	   pulmonary	   exacerbation	   compared	   to	   those	   with	   emphysema,	   however	  
those	   with	   more	   severe	   bronchiectasis	   did	   report	   significantly	   poorer	   health	   status	  
outcomes.	  Determining	  why	  this	  occurs	  is	  an	  important	  area	  of	  research.	  
It	  has	  been	  ten	  years	  since	  Ireland	  became	  the	  first	  country	  in	  the	  world	  to	  introduce	  a	  
ban	  on	  smoking	  in	  the	  workplace(24).	  Passive	  smoke	  exposure	  is	  a	  known	  risk	  factor	  for	  
the	  development	  of	  emphysema	  and	  COPD,	  individuals	  with	  AATD	  are	  particularly	  at	  risk	  
and	  have	  most	  to	  benefit	  from	  public	  health	  initiatives	  that	  reduce	  cumulative	  lifetime	  
smoke	  exposure	  (25).	  The	  fact	  that	  no	  individual	  reported	  an	  increase,	  and	  the	  majority	  
reported	   a	   decrease,	   in	   passive	   smoke	   exposure	   speaks	   to	   the	   success	   of	   this	  
programme	  pioneered	   in	   Ireland	  and	  emulated	  worldwide	   (24).	  Apart	   from	   increasing	  
the	   cumulative	   lifetime	   exposure	   to	   tobacco	   smoke,	   the	   results	   of	   this	   study	   indicate	  
that	   passive	   smoke	   exposure	   in	   childhood,	   in	   particular	   parental	   smoking,	   influence	  
smoking	  habits	  in	  adulthood	  by	  increasing	  the	  likelihood	  of	  ever	  smoking	  and	  the	  total	  
pack	  year	  cigarette	  consumption.	  Further	  efforts	   to	  reduce	  passive	  smoke	  exposure	   in	  
automobiles	  are	  welcome	   initiatives	   that	  are	  undergoing	   legislative	   implementation	   in	  
some	  countries	  at	  present	  (26).	  
The	   study	   of	   PiMZ	   individuals	   identified	   from	   probands	   in	   the	   Irish	   National	   AATD	  
Registry	  has	  significantly	  improved	  our	  understanding	  of	  the	  risk	  of	  lung	  disease	  in	  this	  
large	   population	   group	   (15).	   A	   significant	   proportion	   of	   the	   severely	   deficient	   AATD	  
population	   in	   the	   Irish	   registry	   are	   compound	  heterozygote	   PiSZ	   individuals,	   a	   finding	  
reflected	   in	   reports	   from	   other	   national	   registries	   (14).	   Despite	   a	   growing	   number	   of	  
known	  PiSZ	   individuals	   there	   is	   a	  paucity	  of	   data	   in	   relation	   to	  outcomes	  of	   this	  AAT-­‐
deficient	   phenotype	   (4).	   Airflow	   obstruction	   appears	   to	   be	   milder	   and	   less	   common	  
compared	  to	  PiZZ	  individuals,	  however	  the	  PiSZ	  phenotype	  is	  associated	  with	  significant	  
risk	  of	  COPD	  in	  smokers	  (27).	  	  
Inclusion	   of	   rare	   SERPINA1	   mutations	   in	   national	   registry	   databases	   permits	  
epidemiological	   study	   regarding	   allele	   frequency	   and	   facilitates	   research	   collaboration	  
to	   gain	   a	   deeper	   understanding	   of	   the	   effects	   of	   abnormal	   AAT	   protein	   production.	  
Centres	   with	   expertise	   in	   genetic	   sequencing	   techniques	   have	   included	   increasing	  
numbers	  of	  rare	  mutations	  identified	  through	  targeted	  detection	  programs	  (28).	  In	  the	  
Irish	   National	   Targeted	   Detection	   Programme,	   approximately	   1.5%	   of	   AATD	   cases	  
detected	  possess	  a	  rare	  SERPINA1	  mutation.	  	  	  
Conclusion	  
National	   registries	   play	   an	   important	   role	   in	   evaluating	   the	   natural	   history	   and	  
progression	   of	   pulmonary	   and	   liver	   disease	   in	   AATD	   and	   contribute	   to	   our	  
understanding	   of	   the	   interaction	   between	   genetic	   susceptibility	   and	   environmental	  
exposure	   in	   this	   population.	   This	   registry	   study	   illustrates	   the	   detrimental	   effect	   of	  
smoke	   exposure	   on	   the	   clinical	   phenotype	   of	   AATD	   in	   Ireland	   and	   the	   benefit	   of	  
immediate	  smoking	  cessation	  at	  any	  stage	  of	  lung	  disease.	  Our	  data	  would	  support	  the	  
premise	   that	  asymptomatic	   individuals	  with	  AATD	  who	  are	  not	  exposed	   to	   smoke	  are	  
likely	   to	   be	   unaffected	   by	   pulmonary	   complications	   in	   their	   lifetime.	   Public	   health	  
initiatives	   to	   reduce	   smoking	   uptake,	   promote	   smoking	   cessation	   and	   reduce	   passive	  
smoke	  exposure	  are	  likely	  to	  be	  of	  most	  benefit	  to	  individuals	  with	  AATD	  that	  have	  yet	  
to	  be	  diagnosed.	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Figure 1:  
A) Correlation of DLCO with FEV1 (r=0.73, p<0.0001) and a DCLO value <50% had a 96.7% 
sensitivity for the requirement for portable O2. B) Significant correlation between emphysema 
severity and DLCO% predicted, r=0.83, p<0.0001. C) Increased severity of emphysema 
detected at an earlier age is observed in smokers, milder emphysema severity is observed in 
never smokers occurring at a later age. D) There was no significant relationship between 
severity of CT detected bronchiectasis and emphysema, r=-0.1664 (p=0.1625). E) Increased CT 
detected bronchiectasis with advancing age, no significant difference in ever-smokers vs. never 
smokers is observed.  F) Increased total pack year smoking history in AATD individuals exposed 
to passive smoke in childhood (17.25 vs. 9.84 pack years smoking, p=0.003). 
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Supplementary Figure: 
A) Similar age-adjusted FEV1 values between index and non-index cases (p=0.51). B) Linear 
regression analysis reveals similar rates of FEV1 decline between ever smokers and never 
smokers despite initial lower FEV1 values in ever smokers (-49mls/annum vs. -26mls/annum, 
p=0.81).  C) Age adjusted FEV1 values in symptomatic (index) never smokers are lower than 
asymptomatic (non-index) never smokers (mean FEV1 77% vs. 95%, p=0.042). D) Age 
adjusted DLCO values in symptomatic (index) never smokers are lower than asymptomatic 
(non-index) never smokers (mean FEV1 64% vs. 83%, p=0.006). Multiple regression analysis 
confirmed significantly lower DCLO % predicted values in symptomatic vs. asymptomatic never 
smokers (-9.96%, 95% C.I -4.6 to -19.5%, p=0.04).  
	  	  
Total	   Ever	  Smoker	   Never	  Smoker	   p-­‐value	  
Male	  	   61/107	  (57)	   39/71	  (55)	   22/36	  (61.1)	   ns	  
Age	  	  	   53	  ±12	   53	  ±11	  	   53	  	  ±15	   ns	  
Age	  at	  diagnosis	  	  	  	   44	  ±13	  	   44	  ±12	  	   44	  ±15	  	   ns	  	  
BMI	  	  	   26.5	  ±5.5	   27.16	  ±5.9	   25.2	  ±4.1	   ns	  
FEV1	  (%	  predicted)	  	  	   63	  ±32	   53	  ±29	  	   84	  ±27	   <0.0001	  
FVC	  (%	  predicted)	  	  	   100	  ±24	  	   96	  ±26	  	   107	  ±17	  	   ns	  
FEV1/FVC	  	  	   0.50	  ±0.2	  	   0.44	  ±0.17	  	   0.64	  ±0.19	  	   <0.0001*	  
DLCO	  (%	  predicted)	  	  	   55.6	  ±23.2	  	   47.9	  ±20	  	   71	  ±22.5	  	   <0.0001*	  
Exacerbations:	  Past	  year	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  years	  
2.1	  ±2.6	  
3.6	  ±4.2	  	  
2.4	  ±2.9	  	  
4.4	  ±4.8	  	  
1.5	  ±1.9	  	  
2.1	  ±1.9	  	  
0.0386	  
0.0041	  
mMRC	  	  	   1.6	  ±1.2	   1.9	  ±1.16	  	   0.9	  ±1.2	  	   <0.0001	  
Pack	  year	  smoking	  	  	   13.6	  ±14	  	   20.5	  ±12	  	   -­‐	   N/A	  
Cough	  	  	   47/107	  (43.9)	   33/71	  (46.5)	   14/36	  (38.9)	   ns	  
Sputum	  production	  	  	   60/107	  (56.1)	   47/71	  (66.2)	   13/36	  (36.1)	   0.004*	  
VAS	  health	  status	  	  	   58	  ±21.8	  	   52.2	  ±21.4	   69.6	  ±17.8	  	   <0.0001	  
Childhood	  passive	  smoke	  
exposure	  
88/107	  (82.2)	   62/71	  (87.3)	   26/36	  (72.2)	   0.0646	  
Annual	  FEV1	  decline	  	  	   -­‐41.6	  ±90.4	  	   -­‐48.9	  ±80	  	   -­‐26.4	  ±109.1	  	   0.81	  
Emphysema	  	  	   8.3	  ±6.2	  	   10.6	  ±5.2	  	   3.2	  ±5.0	  	   <0.0001*	  
Bronchiectasis	  	  	   3.7	  ±3.6	  	   3.0	  ±3.1	  	   5.1	  ±4.1	  	   0.02*	  
	  
	   	  
Table 1: Univariate analysis of ever smokers vs. never smokers 
Data are presented as n (%), mean ± SD unless otherwise stated.  
BMI: body mass index; FEV1: forced expiratory volume in 1s (% predicted); 
FVC: forced vital capacity; DCLO: diffusing capacity of the lung for CO. 
mMRC: modified Medical Research Council dyspnoea score; VAS: Visual 
Analogue Scale health statue in the past week. 
* Significant on multivariate analysis (p<0.05). 
	   Total	   Index	  	   Non-­‐index	   p-­‐value	  
Male	  	  	   61/107	  (57)	   43/72	  (59.7)	   18/35	  (51.4)	   ns	  
Age	  	  	   53	  ±12	   54	  ±13	   51	  ±11	  	  	   ns	  
Age	  at	  diagnosis	  	  	  	   44	  	  ±13	  	   45.3	  ±14	   42	  ±12	  	   ns	  
BMI	  	  	   26.5	  ±5.4	  	   26.2	  ±5.7	  	   27.2	  ±5.0	  	   ns	  
FEV1	  (%	  predicted)	   63	  ±32	  	   58	  ±30	   74	  ±34	  	   0.03	  
FVC	  (%	  predicted)	  	   100	  ±24	   98	  ±23.	  	   102	  ±25	   ns	  
FEV1/FVC	  	  	   0.51	  ±0.2	  	   0.47	  ±0.2	  	   0.58	  ±0.2	  	   0.01	  
DLCO	  (%	  predicted)	  	  	   55.6	  ±23.2	  	   51.1	  ±20.7	  	   64.2	  ±25.5	  	   0.01*	  
Exacerbations:	  Past	  year	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  years	  
2.1	  ±2.6	  
3.6	  ±4.2	  
2.3	  ±2.7	  	  
3.8	  ±3.6	  	  
1.7	  ±2.4	  
3.4	  ±5.2	  	  
ns	  	  
ns	  
mMRC	  	  	   1.6±1.2	  	   1.6	  ±1.2	  	   1.6	  ±1.3	   ns	  
Pack	  year	  smoking	  	  	   13.6	  ±14	  	   13.4	  ±12.8	   14	  ±16.5	   ns	  
Never	  smoker	  	  	   36/107	  (33.6)	   23/72	  (32)	   13/35	  (37.1)	   ns	  
Cough	  	  	   47/107	  (43.9)	   32/72	  (44.4)	   15/35	  (42.9)	   ns	  
Sputum	  production	  	  	   60/107	  (56.1)	   41/72	  (57)	   19/35	  (54.2)	   ns	  
VAS	  health	  status	  	  	   58.1	  ±21.8	  	   56.5	  ±20.4	  	   61.4	  ±24.4	  	   ns	  
Childhood	  passive	  
smoke	  exposure	  	  	  
88/107	  (82.2)	   61/72	  (84.7)	   27/35	  (77.1)	   ns	  
Annual	  FEV1	  decline	  	  	   -­‐41.6	  ±90.4	  	   -­‐36.4	  ±85.4	  	   -­‐51.3	  ±100.0	  	   ns	  
Emphysema	  	  	   8.3	  ±6.2	  	   9.6	  ±5.5	   5.5	  ±6.2	  	   0.01	  
Bronchiectasis	  	  	   3.7	  ±3.6	   4.23	  	  ±4.1	   2.5	  ±2.2	   ns	  
	  
Supplementary Table:  Univariate analysis of index vs. non-index cases 
Data are presented as n (%), mean ± SD unless otherwise stated.  
BMI: body mass index; FEV1: forced expiratory volume in 1s(% predicted); FVC: 
forced vital capacity; DLCO: diffusing capacity of the lung for CO; mMRC: 
modified Medical Research Council dyspnoea score; VAS: Visual Analogue 
Scale health statue in the past week. 
* Significant on multivariate analysis: (p<0.01). 
